Does Rallies show Form 4 insider transactions for DGX?

Yes. Rallies tracks DGX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is DGX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for DGX. It does not provide personalized investment advice.

DGX (Quest Diagnostics Inc.) Stock Analysis - Insider Trades

Quest Diagnostics Inc. (DGX) is a publicly traded Healthcare sector company. As of May 21, 2026, DGX trades at $193.75 with a market cap of $21.01B and a P/E ratio of 21.18. DGX moved +2.02% today. Year to date, DGX is +11.68%; over the trailing twelve months it is +8.70%. Its 52-week range spans $146.17 to $213.50. Analyst consensus is buy with an average price target of $220.50. Rallies surfaces DGX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading DGX stock inside the company?

Recent DGX insider activity includes Doherty Catherine T. sold 5.56K, PREVOZNIK MICHAEL E sold 3.88K, Plewman Patrick sold 2.85K, KUPPUSAMY KARTHIK sold 2.63K, and Doherty Catherine T. sold 632. Rallies tracks insider transaction dates, shares, prices, and estimated values.

DGX Key Metrics

Key financial metrics for DGX
Metric	Value
Price	$193.75
Market Cap	$21.01B
P/E Ratio	21.18
EPS	$9.17
Dividend Yield	0.86%
52-Week High	$213.50
52-Week Low	$146.17
Volume	0
Avg Volume	0
Revenue (TTM)	$11.28B
Net Income	$1.07B
Gross Margin	33.20%

Recent DGX Insider Trades

Doherty Catherine T. sold 5.56K (~$1.15M) on Mar 5, 2026.
PREVOZNIK MICHAEL E sold 3.88K (~$799.68K) on Mar 5, 2026.
Plewman Patrick sold 2.85K (~$588.73K) on Mar 5, 2026.
KUPPUSAMY KARTHIK sold 2.63K (~$538.37K) on Mar 4, 2026.
Doherty Catherine T. sold 632 (~$131.29K) on Mar 3, 2026.

Latest DGX News

Quest Diagnostics jumps after Q1 beat and raised 2026 revenue, EPS guidance — Apr 30, 2026
Quest Diagnostics drops as CMS “CRUSH” policy overhang hits lab-testing stocks — Apr 29, 2026
Quest Diagnostics Prices $500 M 5.00% Senior Notes Due 2036 — Apr 27, 2026
Quest Diagnostics slides as post-earnings profit-taking hits shares after raised 2026 outlook — Apr 23, 2026
Quest Diagnostics jumps after Q1 2026 beat and higher full-year guidance — Apr 21, 2026

DGX Analyst Consensus

9 analysts cover DGX: 0 strong buy, 4 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $220.50.

Common questions about DGX

Who is trading DGX stock inside the company?: Recent DGX insider activity includes Doherty Catherine T. sold 5.56K, PREVOZNIK MICHAEL E sold 3.88K, Plewman Patrick sold 2.85K, KUPPUSAMY KARTHIK sold 2.63K, and Doherty Catherine T. sold 632. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for DGX?: Yes. Rallies tracks DGX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is DGX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for DGX. It does not provide personalized investment advice.